Oct 25 2024 19 mins
Visit https://www.peervoice.com/VCG860 to view the entire programme with slides. After completing “Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates”, participants will be able to: Describe patient-specific risk factors for the development of antibody-drug conjugate (ADC)-associated nausea/vomiting; and Propose appropriate individualised protocols to optimise emesis control in patients receiving an ADC that is classified as having medium-high/high emetic risk.